文献速递糖尿病

妊娠期糖尿病胰岛素和/或口服降糖药治疗女性1年及以后随访的核心结局集:Delphi调查

Follow-up at 1 year and beyond of women with gestational diabetes treated with insulin and/or oral glucose-lowering agents: a core outcome set using a Delphi survey.
PubMed 文献 · Diabetologia · 2019-07-04

本研究旨在为接受胰岛素和/或口服降糖药治疗的妊娠期糖尿病(GDM)女性在产后1年及以后的长期随访研究制定核心结局集(COS)。通过系统综述、三轮在线Delphi调查(第一轮835人受邀,288人应答)和共识会议,最终确定9个核心结局,包括血糖状态评估、2型糖尿病诊断、再次妊娠数、GDM再发、糖尿病前期诊断、BMI、产后体重滞留、静息血压和母乳喂养。该COS有助于提高相关临床试验结局选择与报告的一致性和规范性。

要点

  • 针对GDM产后1年及以后随访研究,建立了包含9个结局的核心结局集。
  • 核心结局涵盖血糖状态、糖尿病诊断、再次妊娠、体重、血压和母乳喂养。
  • 该COS旨在减少报告偏倚,增强研究间可比性。

核心结论

  • 研究确定了9个核心结局,用于GDM女性产后1年及以后随访的临床试验和其他研究,以促进结局选择和报告的一致性。

研究设计与样本

  • 研究包括三个部分:系统综述既往RCT报告的结局;三轮在线Delphi调查(第一轮835人受邀,288人应答;第二轮190/288应答;第三轮165/190应答);共识会议确定最终COS。

主要发现

  • 系统综述从3344篇摘要中筛选出62篇全文,最终纳入25篇,识别出121个结局进入Delphi调查。
  • 最终COS包含9个结局:血糖状态评估、2型糖尿病诊断、再次妊娠数、GDM再发妊娠数、糖尿病前期诊断、BMI、产后体重滞留、静息血压、母乳喂养。

关键数值与推荐

  • 最终核心结局集包含9个结局,具体为:血糖状态评估;自指数妊娠以来诊断的2型糖尿病;自指数妊娠以来的妊娠次数;自指数妊娠以来诊断GDM的妊娠次数;自指数妊娠以来诊断的糖尿病前期;BMI;产后体重滞留;静息血压;母乳喂养。

临床怎么用

  • 建议在GDM女性产后1年及以后的随访研究中,采用这9个核心结局进行选择和报告,以提高研究间的可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Gestational diabetes mellitus (GDM) is linked with a higher lifetime risk for the development of impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, the metabolic syndrome, cardiovascular disease, postpartum depression and tumours. Despite this, there is no consistency in the long-term follow-up of women with a previous diagnosis of GDM. Further, the outcomes selected and reported in the research involving this population are heterogeneous and lack standardisation. This amplifies the risk of reporting bias and diminishes the likelihood of significant comparisons between studies. The aim of this study is to develop a core outcome set (COS) for RCTs and other studies evaluating the long-term follow-up at 1 year and beyond of women with previous GDM treated with insulin and/oral glucose-lowering agents. METHODS: The study consisted of three work packages: (1) a systematic review of the outcomes reported in previous RCTs of the follow-up at 1 year and beyond of women with GDM treated with insulin and/or oral glucose-lowering agents; (2) a three-round online Delphi survey with key stakeholders to prioritise these outcomes; and (3) a consensus meeting where the final COS was decided. RESULTS: Of 3344 abstracts identified and evaluated, 62 papers were retrieved and 25/62 papers were included in this review. A total of 121 outcomes were identified and included in the Delphi survey. Delphi round 1 was emailed to 835 participants and 288 (34.5%) responded. In round 2, 190 of 288 (65.9%) participants responded and in round 3, 165 of 190 (86.8%) participants responded. In total, nine outcomes were selected and agreed for inclusion in the final COS: assessment of glycaemic status; diagnosis of type 2 diabetes since the index pregnancy; number of pregnancies since the index pregnancy; number of pregnancies with a diagnosis of GDM since the index pregnancy; diagnosis of prediabetes since the index pregnancy; BMI; post-pregnancy weight retention; resting blood pressure; and breastfeeding. CONCLUSIONS/INTERPRETATION: This study identified a COS that will help bring consistency and uniformity to outcome selection and reporting in clinical trials and other studies involving the follow-up at 1 year and beyond of women diagnosed with GDM treated with insulin and/or oral glucose-lowering agents during pregnancy.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Bogdanet D, Reddin C, Macken E, et al. Follow-up at 1 year and beyond of women with gestational diabetes treated with insulin and/or oral glucose-lowering agents: a core outcome set using a Delphi survey. Diabetologia. 2019. PMID: 31273408. doi:10.1007/s00125-019-4935-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。